Can Estradiol and Ghrelin Play a Protective Role in Epithelial Ovarian Cancer Incidence in Postmenopausal Women?

Fooladi, Saba; Akbari, Hamed; Abolhassani, Moslem; Sadeghi, Erfan; Fallah, Hossein

doi:10.1016/j.arcmed.2020.11.008

Cited by 2 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of acylated ghrelin have also been shown to induce apoptosis in ovarian cancer cells, but it is unclear if this is also due to cytotoxicity [15,35]. Higher concentrations of UAG and total ghrelin levels were associated with decreased risk of developing epithelial ovarian cancer in a cohort of post-menopausal women [36]. On the other hand, recently an in vitro study found that lower doses of ghrelin significantly increase cell proliferation of the A2870 ovarian cancer cells (Table 1).…”

Section: Acylated Ghrelin (Ag) and Unacylated Ghrelin (Uag)mentioning

confidence: 99%

Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression

et al. 2022

View full text Add to dashboard Cite

Ghrelin, a hormone produced and secreted from the stomach, is prim arily known as an appetite stimulant. Recently, it has emerged as a potential regulator/biomarker of cancer progression. Inconsistent results on this subject make this body of literature difficult to interpret. Here, we attempt to identify commonalities in the relationships between ghrelin and various cancers, and summarize important considerations for future research. The main players in the ghrelin family axis are unacylated ghrelin (UAG), acylated ghrelin (AG), the enzyme ghrelin O-acyltransferase (GOAT), and the growth hormone secretagogue receptor (GHSR). GOAT is responsible for the acylation of ghrelin, after which ghrelin can bind to the functional ghrelin receptor GHSR-1a to initiate the activation cascade. Splice variants of ghrelin also exist, with the most prominent being In1-ghrelin. In this review, we focus primarily on the potential of In1-ghrelin as a biomarker for cancer progression, the unique characteristics of UAG and AG, the importance of the two known receptor variants GHSR-1a and 1b, as well as the possible mechanisms through which the ghrelin axis acts. Further understanding of the role of the ghrelin axis in tumor cell proliferation could lead to the development of novel therapeutic approaches for various cancers.

show abstract

Section: Acylated Ghrelin (Ag) and Unacylated Ghrelin (Uag)mentioning

confidence: 99%

Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ghrelin is an adipocyte-derived orexigenic hormone and an endocrine regulatory peptide that serves multiple functions such as increasing appetite and regulating a number of biological cardiovascular processes 8 13 14. Non-acylated ghrelin, which is the most abundant form of circulating ghrelin (80%–90%), has been demonstrated to exhibit growth hormone (GH)-releasing capacity.…”

Section: Introductionmentioning

confidence: 99%

Ghrelin and Ghrelin/Total Cholesterol Ratio as Independent Predictors for Coronary Artery Disease: A Systematic Review and Meta-Analysis

Niknam

Liaghat

Zarghami

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

The present meta-analysis aimed to summarize the available data regarding the circulating levels of ghrelin in patients with cardiovascular diseases (CVDs). A comprehensive search was performed in electronic databases including PubMed, Scopus, EMBASE, and Web of Science up to January 20, 2021. Since the circulating levels of ghrelin were measured in different units across the included studies, they were expressed as the standardized mean difference (SMD) and 95% CI (summary effect size). A random-effects model comprising the DerSimonian and Laird method was used to pool SMDs. Sixteen articles (20 studies) comprised of 1087 cases and 437 controls were included. The pooled results showed that there were no significant differences between cases and controls in terms of ghrelin levels (SMD=−0.61, 95% CI −1.38 to 0.16; p=0.120; I2=96.9%, p<0.001). The ghrelin concentrations in the CAD stratum were significantly lower than in controls, whereas they increased in other disease strata. New combined biomarkers demonstrated a significant decrease in the SMD of the ghrelin/total cholesterol (TC) ratio (−1.02; 95% CI −1.74 to –0.29, p=0.000; I2=94.5%). However, no significant differences were found in the SMD of the ghrelin/high-density lipoprotein cholesterol ratio, ghrelin/low-density lipoprotein cholesterol ratio, and ghrelin/triglyceride (TG) ratio in cases with CVDs compared with the control group. Ghrelin was associated with CAD; therefore, it may be considered a biomarker for distinguishing between patients with and without CAD. Furthermore, the ghrelin/TC ratio could be proposed as a diagnostic marker for CVD.

show abstract

Can Estradiol and Ghrelin Play a Protective Role in Epithelial Ovarian Cancer Incidence in Postmenopausal Women?

Cited by 2 publications

References 47 publications

Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression

Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression

Ghrelin and Ghrelin/Total Cholesterol Ratio as Independent Predictors for Coronary Artery Disease: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About